Acorda Therapeutics Inc (ACOR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Acorda Therapeutics Inc (ACOR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9870
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:69
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Acorda Therapeutics Inc (Acorda) is a biopharmaceutical company that discovers, develops, and commercializes therapies for treating patients with neurological disorders. Its portfolio encomppases marketed products for the treatment of multiple sclerosis (MS); and for the management of spasticity; and neuropathic pain associated with post-herpetic neuralgia. It is also developing a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine, MS, heart failure and spinal cord injury. Acorda sells its products through wholesale pharmaceutical distributors to retail pharmacies and specialty pharmacy providers. It has subsidiaries in the US and Europe. Acorda is headquartered in Ardsley, New York, the US.

Acorda Therapeutics Inc (ACOR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 13
Venture Financing 15
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 17
Private Equity 19
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Partnerships 20
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
Licensing Agreements 22
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Equity Offering 23
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 28
Debt Offering 29
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Asset Transactions 33
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Acquisition 34
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 39
Acorda Therapeutics Inc – Key Competitors 40
Acorda Therapeutics Inc – Key Employees 41
Acorda Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 44
Strategy And Business Planning 44
Apr 05, 2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 44
Financial Announcements 45
Oct 31, 2018: Acorda provides financial and pipeline update for third quarter 2018 45
Aug 02, 2018: Acorda provides financial and pipeline update for second quarter 2018 47
May 02, 2018: Acorda Provides Financial and Pipeline Update for First Quarter 2018 48
Feb 15, 2018: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2017 50
Jan 08, 2018: Acorda Announces 2017 AMPYRA Net Sales and Provides 2018 Financial Guidance at J.P. Morgan Healthcare Conference 52
Oct 31, 2017: Acorda Provides Financial and Pipeline Update for Third Quarter 2017 54
Jul 27, 2017: Acorda Provides Financial and Pipeline Update for Second Quarter 2017 56
Apr 27, 2017: Acorda Provides Financial and Pipeline Update for First Quarter 2017 58
Feb 14, 2017: Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2016 60
Corporate Communications 62
Feb 21, 2017: Catherine D. Strader, Ph.D., Joins Acorda Therapeutics Board of Directors 62
Product News 63
04/05/2017: Acorda Therapeutics Implements Corporate Restructuring to Align Cost Structure with Focus on Promising Late-Stage Programs 63
Clinical Trials 64
Jun 06, 2017: Acorda Presenting New Tozadenant Data at 2017 MDS Congress 64
Mar 29, 2017: Acorda Announces Long-Term Safety Data for CVT-301 65
Feb 09, 2017: Acorda Announces Positive Phase 3 Clinical Trial Results for CVT-301 67
Appendix 69
Methodology 69
About GlobalData 69
Contact Us 69
Disclaimer 69

List of Tables
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Acorda Therapeutics Completes Acquisition Of Rights To Qutenza And NGX-1998 From NeurogesX For US$13 Million 13
Civitas Therapeutics Raises USD55 Million in Series C Financing 15
Civitas Therapeutics Raises US$38 Million In Series B Venture Financing 17
Acorda Therapeutics Receives USD40 Million Royalty from HealthCare Royalty 19
Zacharon Pharma Enters Into Research Agreement With Acorda Therapeutics 20
Acorda Therapeutics Enters Into Co-Marketing Agreement With Watson For ZANAFLEX CAPSULES 21
H. Lundbeck Amends Licensing Agreement With Biotie Therapies For Selincro 22
Acorda Therapeutics Plans to Raise Funds through Rights Offering of Preferred Shares 23
Acorda Therapeutics Raises USD75 Million in Private Placement of Shares 24
Biotie Therapies Raises USD56.6 Million in Public Offering of ADSs 25
Civitas Therapeutics Withdraw IPO for up to USD80 million 27
Biotie Therapies Completes Private Placement Of Shares For US$25 Million 28
Biotie Therapies to Raise USD45.6 Million in Private Placement of Notes and Warrants 29
Acorda Therapeutics Raises USD345 Million in Public Offering of Notes Due 2021 31
Grunenthal Acquires Additional Rights for Qutenza from Acorda Therapeutics 33
Biogen and UCB May Acquire Acorda Therapeutics 34
Acorda Therapeutics Rejects Plan of its Sale 35
Acorda Therapeutics Acquires Biotie Therapies in Tender Offer 36
Acorda Therapeutics Acquires Civitas Therapeutics for USD525 Million 38
Lundbeck Acquires 4.6% Stake In Biotie Therapies For US$13 Million 39
Acorda Therapeutics Inc, Key Competitors 40
Acorda Therapeutics Inc, Key Employees 41
Acorda Therapeutics Inc, Subsidiaries 42

List of Figures
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Acorda Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Acorda Therapeutics Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Acorda Therapeutics Inc (ACOR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Verrica Pharmaceuticals Inc (VRCA):製薬・医療:M&Aディール及び事業提携情報
    Summary Verrica Pharmaceuticals Inc (Verrica) is a clinical-stage medical dermatology company that discovers, develops and commercializes therapeutics for the treatment of skin diseases. The company’s lead product candidate, VP-102, is in two phase 3 clinical trials for the treatment of molluscum co …
  • Immucor, Inc.:企業の戦略的SWOT分析
    Immucor, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Noevir Holdings Co Ltd (4928):企業の財務・戦略的SWOT分析
    Noevir Holdings Co Ltd (4928) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Egmont International Holding AS:企業の戦略的SWOT分析
    Egmont International Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • SRF Ltd (SRF):企業の財務・戦略的SWOT分析
    SRF Ltd (SRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Advantage Oil & Gas Ltd. (AAV):石油・ガス:M&Aディール及び事業提携情報
    Summary Advantage Oil & Gas Ltd (Advantage Oil & Gas) is an upstream company. It is involved in exploitation, acquisition, development, and production of crude oil, natural gas and natural gas liquids in Alberta. The company’s exploitation and development program is focused on Glacier assets and the …
  • Beacon Discovery Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Beacon Discovery Inc (Beacon Discovery) is an independent drug discovery incubator that focuses on identifying and advancing molecules targeting G-Protein Coupled Receptors (GPCRs) from concept to clinic. The company works in collaboration with pharma and biotech companies to discover and de …
  • Ildong Pharmaceutical Co Ltd (000230):企業の財務・戦略的SWOT分析
    Summary Ildong Pharmaceutical Co Ltd (IPC) is a manufacturer of pharmaceutical products. The company offers finished drugs, health foods and foods, raw material drugs, cosmetics and medical devices and others. Its raw material drugs comprise synthesis, probiotics, vitamins and biometabolites. IPC al …
  • Raley’s Family of Fine Stores:企業の戦略的SWOT分析
    Raley's Family of Fine Stores - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Par Pacific Holdings Inc (PARR):石油・ガス:M&Aディール及び事業提携情報
    Summary Par Pacific Holdings Inc (Par Pacific), formerly known as Par Petroleum Corporation, manages, owns and maintains interests in energy and infrastructure related businesses. It has operations across the value chain from natural gas production to distribution and transportation. The company con …
  • Surge Energy Inc (SGY):企業の財務・戦略的SWOT分析
    Summary Surge Energy Inc (Surge) is an oil and gas company that offers acquisitions, exploration and production of crude oil and natural gas reserves. The company provides risk management and risk development drilling services. Its oil and natural gas producing properties include Shaunavon and Dodsl …
  • Spineology Inc:医療機器:M&Aディール及び事業提携情報
    Summary Spineology Inc (Spineology) is a medical device company that develops and designs spinal implants. The company offers products such as pedicular fixation system, interbody fusion system, deployable grafting system, amniotic fixation system, allografts, retractor system, liquid tissue matrix, …
  • The Star Entertainment Group Ltd:企業の戦略・SWOT・財務情報
    The Star Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report Summary The Star Entertainment Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • LyondellBasell Industries NV (LYB)-石油・ガス分野:企業M&A・提携分析
    Summary LyondellBasell Industries N.V. (LyondellBasell) is a chemical company. It produces and sells petrochemicals, plastics and basic chemicals. The company also refines crude oil to convert into refined products such as gasoline, diesel and jet fuel. Its major chemical products include polyolefin …
  • Rohto Pharmaceutical Co Ltd (4527):企業の財務・戦略的SWOT分析
    Rohto Pharmaceutical Co Ltd (4527) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Orlando Utilities Commission:企業の戦略的SWOT分析
    Orlando Utilities Commission - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Safety-Kleen Inc:企業の戦略的SWOT分析
    Safety-Kleen Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Instrumentation Laboratory Co:企業の戦略的SWOT分析
    Instrumentation Laboratory Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Qatar Islamic Bank:企業の戦略・SWOT・財務分析
    Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report Summary Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • PLT Health Solutions Inc:企業の戦略・SWOT・財務分析
    PLT Health Solutions Inc - Strategy, SWOT and Corporate Finance Report Summary PLT Health Solutions Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆